Dr Marina Garassino speaks to ecancer about the longer follow-up of the MARIPOSA study. The updated analysis compared the effectiveness of the combination of amivantamab and lazertinib with osimertinib.

The study results indicated that amivantamab and lazertinib continue to demonstrate a trend towards improved overall survival and better post-progression outcomes compared to osimertinib.

This reaffirms that amivantamab-lazertinib is a first-line standard-of-care treatment for EGFR-mutated advanced NSCLC.